A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its ...

For example, revenue from breast cancer drug Ibrance and prostate cancer treatment Xtandi have declined in recent months. Pfizer has shared those funds with Astellas Pharma since 2009 ...

Developing drugs to treat cancer is a major part of pharmaceutical giant Pfizer's future strategy. Pfizer already has a presence in treatments for breast cancer and prostate cancer but is working ...

Pfizer Inc, beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company ...

Pfizer’s $14 billion deal to buy San Francisco’s Medivation Inc. gives the pharmaceutical giant a blockbuster prostate-cancer drug that strengthens its line of lucrative therapies. In making ...

Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their prostate cancer drug met the main goal of a trial testing it for a more common form of the disease. The drug, Xtandi, is already ...

Before the Seagen deal, Pfizer’s top three cancer drugs—Ibrance ... of its PARP inhibitor Talzenna and Xtandi to a broader prostate cancer population. Besides, the company is looking to ...

Oct 10 (Reuters) - Pfizer (PFE.N), opens new tab said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of advanced prostate cancer in a ...

Pfizer Inc. shares ticked higher in the extended session Monday after the drug maker said the Food ... with metastatic castration-sensitive prostate cancer, or prostate cancer that spreads to ...

Medivation, which makes the big-selling drug Xtandi to treat prostate cancer, has finally found its buyer in a fellow U.S. drugmaker, Pfizer. Pharmaceutical companies from all over the world ...